ArticleFrontiers in pharmacology2025
Multi-target approach of Egyptian leek extract in ameliorating depressive-like behavior in rats exposed to chronic unpredictable mild stress.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Butyrate Is Associated with the Antidepressant Effects ofInternational journal of molecular sciences · 2026Article
- Neuroprotective effects of rutin, sodium selenite, and rutin-conjugated selenium nanoparticles in a social isolation model.Frontiers in pharmacology · 2026Article
- Epigallocatechin-3-gallate conjugated with selenium nanoparticles prevents neurological complications in rats exhibiting schizophrenia-like behaviors.Frontiers in pharmacology · 2025Article
- Studying the potential ameliorative effect of biosynthesized selenium nanoparticles using epigallocatechin gallate against depression in rats.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Depression is a widespread and debilitating disorder with a complex etiology involving oxidative stress, neuroinflammation, and apoptosis. Given the limitations of current treatments, there is an urgent need for alternative therapeutic approaches. This study evaluated the antidepressant effects of Egyptian leek (Allium ampeloprasum var. kurrat) in rats exposed to chronic unpredictable mild stress (CUMS), a well-established model for studying depression, while exploring the underlying molecular mechanisms. Egyptian leek extract is rich in bioactive compounds, including flavonoids, alkaloids, terpenoids, steroids, and saponins, which are known for their neuroprotective and mood-regulating properties. Methods: Using liquid chromatography-mass spectrometry (LC-MS) and Fourier-transform infrared spectroscopy (FT-IR), the leek extract was analyzed to identify bioactive compounds. In this study, CUMS-exposed rats were treated with the extract, and their behavior was assessed using the sucrose preference test (SPT), open field test (OFT), and social interaction test (SIT). Concurrently, oxidative stress and antioxidant factors, pro-inflammatory cytokines, and apoptotic proteins in the cerebral cortex were evaluated, and molecular docking analyses were conducted to investigate the extract's mechanisms of action. Results: The results demonstrated that treatment with Egyptian leek extract significantly alleviated depression-like behaviors, as evidenced by improved performance in the SPT, OFT, and SIT. Moreover, the leek extract improved oxidative stress parameters, reduced levels of pro-inflammatory cytokines, suppressed NF-κB activation, and promoted neuronal survival by modulating apoptosis-related proteins. Discussion: These results suggest that the leek extract effectively mitigates oxidative stress, inflammation, and apoptosis, thereby contributing to its overall antidepressant effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.